ANDA 209613, held by Amneal Pharms Co. Teriflunomide.
As of Nov 16, 2026, ANDA 209613 (Teriflunomide), held by Amneal Pharms Co, was first approved by FDA on Sep 28, 2018, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 28, 2018 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Discontinued |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Discontinued |
| Mar 26, 2025 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 26, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 20, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 5, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 29, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 28, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters